Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?

Journal Article (Journal Article;Review)

NK cells play a critical role in antiviral and antitumor responses. Although current NK cell immune therapies have focused primarily on cancer biology, many of these advances can be readily applied to target HIV/simian immunodeficiency virus (SIV)-infected cells. Promising developments include recent reports that CAR NK cells are capable of targeted responses while producing less off-target and toxic side effects than are associated with CAR T cell therapies. Further, CAR NK cells derived from inducible pluripotent stem cells or cell lines may allow for more rapid "off-the-shelf" access. Other work investigating the IL-15 superagonist ALT-803 (now N803) may also provide a recourse for enhancing NK cell responses in the context of the immunosuppressive and inflammatory environment of chronic HIV/SIV infections, leading to enhanced control of viremia. With a broader acceptance of research supporting adaptive functions in NK cells it is likely that novel immunotherapeutics and vaccine modalities will aim to generate virus-specific memory NK cells. In doing so, better targeted NK cell responses against virus-infected cells may usher in a new era of NK cell-tuned immune therapy.

Full Text

Duke Authors

Cited Authors

  • Ram, DR; Manickam, C; Lucar, O; Shah, SV; Reeves, RK

Published Date

  • June 2019

Published In

Volume / Issue

  • 105 / 6

Start / End Page

  • 1253 - 1259

PubMed ID

  • 30730588

Pubmed Central ID

  • PMC6536345

Electronic International Standard Serial Number (EISSN)

  • 1938-3673

Digital Object Identifier (DOI)

  • 10.1002/JLB.MR0718-303R


  • eng

Conference Location

  • United States